New combo therapy aims to slash liver cancer recurrence before surgery
Disease control
Not yet recruiting
This study tests whether giving a combination of drugs (sintilimab, bevacizumab, and chemotherapy) along with liver-directed treatments before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 adults with resectable liver cancer …
Phase: PHASE1, PHASE2 • Sponsor: BinYong Liang • Aim: Disease control
Last updated May 04, 2026 05:18 UTC